Pharma channel feed

As­traZeneca ex­pands stake in cell and gene ther­a­py part­ner Cel­lec­tis

Last year
Financing
Cell/Gene Tx

Pfiz­er hires Citi an­a­lyst Baum to over­see port­fo­lio strat­e­gy

Last year
People

J&J show­cas­es more blad­der can­cer re­sults from 'pret­zel' drug-de­vice com­bo

Last year
R&D

Sen­a­tors from both par­ties in­tro­duce menopause re­search bill

Last year

Ab­b­Vie puts $161M in­to new R&D site in Ger­many, will add 300 jobs

Last year
R&D

House to mark up bill tar­get­ing Chi­nese biotech and ge­nomics com­pa­nies

Last year
China

Dig­i­tal health start­up Ro’s CEO talks GLP-1 drug pric­ing, short­ages and com­pound­ed shots

Last year
Health Tech

Bi­par­ti­san draft bill would pay hos­pi­tals more to com­bat drug short­ages

Last year
Manufacturing

Phar­ma com­pa­nies soft­en tone on full IRA im­pact

Last year

Block­buster can­cer drug Calquence hits pri­ma­ry end­point in tri­al for first-line man­tle cell lym­phoma

Last year
R&D

ICER push­es back on FDA's po­ten­tial con­ver­sion of Sarep­ta's gene ther­a­py to full ap­proval

Last year
Cell/Gene Tx
FDA+

No­vo nabs over a third of di­a­betes mar­ket, a year ahead of sched­ule

Last year

Mod­er­na sticks to long-term strat­e­gy in first-quar­ter up­date, ends pact with Metageno­mi

Last year

FDA asks for more da­ta on Dupix­ent in COPD in move that could de­lay a de­ci­sion

Last year
R&D
FDA+

No­var­tis makes a $1B ra­dio­phar­ma deal, buy­ing Mar­i­ana On­col­o­gy

Last year
Startups
Deals

No­vo’s GLP-1 sales boost prof­its, yet full po­ten­tial still curbed by sup­ply squeeze

Last year

J&J fol­lows Bris­tol My­ers in ap­peal of judge's rul­ing against com­pa­nies in IRA law­suit

Last year
Law

Pfiz­er sticks to the script in first-quar­ter up­date as cost cuts are 'large­ly com­plete'

Last year

Boehringer puts a tar­get on Hu­mi­ra, says push­ing it off for­mu­la­ries is nec­es­sary

Last year

J&J pro­pos­es $6.5B talc set­tle­ment plan

Last year
Law

Sen­a­tor al­leges GSK is shirk­ing its com­mit­ment to low­er in­haler costs

Last year
FDA+

GSK ex­pe­dites Blenrep time­lines as it eyes sec­ond chance in mul­ti­ple myelo­ma

Last year

GSK still rid­ing vac­cine sales wave, push­ing 2024 fore­casts high­er

Last year

Pfiz­er makes small pipeline changes in first-quar­ter up­date

Last year
First page Previous page 57585960616263 Next page Last page
A service from the Financial Times